Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Retained Earnings (2021 - 2025)

Universe Pharmaceuticals (UPC) has disclosed Retained Earnings for 5 consecutive years, with -$1.8 billion as the latest value for Q3 2025.

  • Quarterly Retained Earnings rose 82.17% to -$1.8 billion in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$1.8 billion through Sep 2025, up 82.17% year-over-year, with the annual reading at -$1.8 billion for FY2025, 82.17% up from the prior year.
  • Retained Earnings hit -$1.8 billion in Q3 2025 for Universe Pharmaceuticals, up from -$10.2 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $2.1 million in Q3 2021 to a low of -$10.2 billion in Q3 2024.
  • Historically, Retained Earnings has averaged -$2.4 billion across 5 years, with a median of -$1.7 million in 2022.
  • Biggest five-year swings in Retained Earnings: tumbled 704170.53% in 2024 and later surged 82.17% in 2025.
  • Year by year, Retained Earnings stood at $2.1 million in 2021, then tumbled by 179.79% to -$1.7 million in 2022, then increased by 13.35% to -$1.4 million in 2023, then crashed by 704170.53% to -$10.2 billion in 2024, then soared by 82.17% to -$1.8 billion in 2025.
  • Business Quant data shows Retained Earnings for UPC at -$1.8 billion in Q3 2025, -$10.2 billion in Q3 2024, and -$1.4 million in Q3 2023.